Drug Profile
RG 6125
Alternative Names: RG6125; SDP-051Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Adheron Therapeutics
- Developer Adheron Therapeutics; Roche
- Class Antifibrotics; Antirheumatics; Monoclonal antibodies
- Mechanism of Action Osteoblast cadherin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Non-alcoholic steatohepatitis; Rheumatoid arthritis
Most Recent Events
- 12 Jun 2019 Efficacy, pharmacokinetic and adverse events data from a phase II trial in Rheumatoid Arthritis presented at the 20th Annual Congress of the European League Against Rheumatism (EULAR-2019)
- 17 Oct 2018 Discontinued - Phase-II for Rheumatoid arthritis in USA (Parenteral) (Roche pipeline, October 2018)
- 17 Oct 2018 Discontinued - Preclinical for Cancer in USA (Parenteral) (Roche pipeline, October 2018)